Biomarkers of Disease Activity, Cure, and Relapse in Tuberculosis - 21/05/15
Doi : 10.1016/j.ccm.2009.08.008
T. Mark Doherty, PhD a, ⁎ 
, Robert S. Wallis, MD, FIDSA b, Alimuddin Zumla, FRCP, PhD(Lond), FRCPath c
, Robert S. Wallis, MD, FIDSA b, Alimuddin Zumla, FRCP, PhD(Lond), FRCPath c a Department of Infectious Disease Immunology, Statens Serum Institute, Artillerivej 5, 2300 København S, Denmark
b Pfizer Global Research & Development, MS 6025 B3149, 50 Pequot Avenue, New London, CT 06320, USA
c University College London Medical School, London, UK
Corresponding author.Résumé |
The changing face of tuberculosis, with epidemics fueled by HIV and urbanization in much of the world and a relative increase in the importance of latent tuberculosis as a source of cases in the more economically developed countries, has led to a demand for more robust, clinically applicable diagnostic tools. As a result, research aiming to identify biomarkers of Mycobacterium tuberculosis infection and disease has flourished. This article discusses the most recent findings of that work.
Le texte complet de cet article est disponible en PDF.Keywords : Tuberculosis, Diagnosis, Biomarkers
Plan
© 2009
Elsevier Inc. Tous droits réservés.
Vol 30 - N° 4
P. 783-796 - décembre 2009 Retour au numéro
Article précédent
- Advances in Immunotherapy for Tuberculosis Treatment
- Gavin J. Churchyard, Gilla Kaplan, Dorothy Fallows, Robert S. Wallis, Philip Onyebujoh, Graham A. Rook
- Tuberculosis-associated Immune Reconstitution Inflammatory Syndrome and Unmasking of Tuberculosis by Antiretroviral Therapy
- Graeme Meintjes, Helena Rabie, Robert J. Wilkinson, Mark F. Cotton
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?